Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GLP1R | P43220 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417783 | 1.00 | EPHX2 (0.65) | EPHX2LPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL4384309 | 0.90 | EPHX2 (0.72) | EPHX2LPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL4384307 | 0.90 | EPHX2 (0.72) | EPHX2LPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL29360245 | 0.87 | CNR1 (0.67) | EPHX2LPAR1LPAR2ENPP2CNR1 | |
| SCHEMBL4397935 | 0.87 | CNR1 (0.67) | EPHX2LPAR1LPAR2ENPP2CNR1 | |
| SCHEMBL24022038 | 0.87 | CNR1 (0.67) | EPHX2LPAR1LPAR2ENPP2CNR1 | |
| SCHEMBL4397932 | 0.87 | CNR1 (0.67) | EPHX2LPAR1LPAR2ENPP2CNR1 | |
| SCHEMBL25835638 | 0.87 | LPAR1 (0.67) | EPHX2LPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL10028552 | 0.86 | SLC6A5 (0.69) | EPHX2LPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL4390152 | 0.85 | EPHX2 (0.63) | EPHX2LPAR1LPAR2ENPP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | EPHX2 3917/4885LPAR1 1089/4885LPAR2 656/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | EPHX2 3342/4885LPAR1 1752/4885LPAR2 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.